Neil E. Alexis, Marianne S. Muhlebach, David B. Peden, Terry L. Noah

Slides:

Advertisements

Similar presentations

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Advertisements

Azithromycin fails to reduce increased expression of neutrophil-related cytokines in primary-cultured epithelial cells from cystic fibrosis mice Ximena.

Monocyte chemoattractant chemokines in cystic fibrosis

Multiple prevalent fractures in relation to macroscopic bone architecture in patients with cystic fibrosis Mirjam Stahl, Christian Holfelder, Carolin.

Charles A. McCaslin, Daniela N. Petrusca, Christophe Poirier, Karina A

Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,

CFTR mutation in an Arab patient: Clinical and functional features of 875+1G→A/875+1G→A genotype Elide Spinelli, Manuela Seia, Paola Melotti, Eleonora.

Zachary M. Sellers, Lori McGlocklin, Andrea Brasch

A small molecule neutrophil elastase inhibitor, KRP-109, inhibits cystic fibrosis mucin degradation Shashi Chillappagari, Christian Müller, Poornima.

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation Venkateshwar Mutyam,

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Regional ventilation in cystic fibrosis measured by electrical impedance tomography Zhanqi Zhao, Rainald Fischer, Inéz Frerichs, Ullrich Müller-Lisse,

Raphaël Chiron, Y. Yaël Grumbach, Nga V. T

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

Delayed publication of clinical trials in cystic fibrosis

Pro-inflammatory effect of cystic fibrosis sputum microparticles in the murine lung Chiara Porro, Sante Di Gioia, Teresa Trotta, Silvia Lepore, Maria.

Fiona K. Dunlevy, S. Lorraine Martin, Francine de Courcey, J

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Expression of the inflammatory regulator A20 correlates with lung function in patients with cystic fibrosis Catriona Kelly, Mark T. Williams, J. Stuart.

Controlled clinical trials in cystic fibrosis — are we doing better?

The glutathione-S-transferase mu 1 (GSTM1) null genotype and increased neutrophil response to low-level ozone (0.06 ppm) Neil E. Alexis, PhD, John C.

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Claire Keating, Armeen D

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

M. Al-Aloul, M. Jackson, G. Bell, M. Ledson, M. Walshaw

Predicting hypoxia in cystic fibrosis patients during exposure to high altitudes Wolfgang Kamin, Birthe Fleck, Dirk-Mathias Rose, Oliver Thews, Wolfgang.

Small macrophages are present in early childhood respiratory disease

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Biological material on inhaled coarse fraction particulate matter activates airway phagocytes in vivo in healthy volunteers Neil E. Alexis, PhD, John.

Jill A. Poole, MD, Neil E. Alexis, PhD, Conrad Parks, BS, Amy K

Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J

Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis Christopher R. Sudfeld, Elliott C. Dasenbrook, William.

Cytokine gene polymorphisms and severity of CF lung disease

Nasal polyposis in lung transplant recipients with cystic fibrosis

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Determining presence of lung disease in young children with cystic fibrosis: Lung clearance index, oxygen saturation and cough frequency E.M. Bakker,

Stability of interleukin 8 and neutrophil elastase in bronchoalveolar lavage fluid following long-term storage Luke J. Berry, Barbara Sheil, Luke Garratt,

Mark R. Johnson, Thomas W. Ferkol, Ross W. Shepherd

Newsome S.J. , Daniel R.M. , Carr S.B. , Bilton D. , Keogh R.H.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Biomarkers for cystic fibrosis lung disease: Application of SELDI-TOF mass spectrometry to BAL fluid Gordon MacGregor, Robert D. Gray, Thomas N. Hilliard,

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

The glutathione-S-transferase Mu 1 null genotype modulates ozone-induced airway inflammation in human subjects Neil E. Alexis, PhD, Haibo Zhou, PhD,

N Dauletbaev, K Viel, R Buhl, T.O.F Wagner, J Bargon

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Treatment intensity and characteristics of MRSA infection in CF

Effect of inhaled endotoxin on airway and circulating inflammatory cell phagocytosis and CD11b expression in atopic asthmatic subjects Neil E. Alexis,

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Neil E. Alexis, PhD, John C. Lay, PhD, Martha Almond, RRT, David B

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin,

Cystic fibrosis and pregnancy in the modern era: A case control study

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Presentation transcript:

Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients Neil E. Alexis, Marianne S. Muhlebach, David B. Peden, Terry L. Noah Journal of Cystic Fibrosis Volume 5, Issue 1, Pages 17-25 (January 2006) DOI: 10.1016/j.jcf.2005.11.001 Copyright © 2005 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 mCD14 (A) and HLA-DR (B) expression (MFI) on CF (N=12, solid bar) and non-CF (N=12, open bar) BALF macrophages and monocytes. mCD14 and HLA-DR expression were significantly (*p<0.05) decreased in CF vs. non-CF subjects. Journal of Cystic Fibrosis 2006 5, 17-25DOI: (10.1016/j.jcf.2005.11.001) Copyright © 2005 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 Phagocytosis of zymosan particles by macrophages and neutrophils recovered from BALF of CF (N=11, solid bar) and non-CF (N=6, open bar) subjects as measured by both mean fluorescence intensity (MFI) (A) and % cells (macrophages, neutrophils) that took up zymosan particles (B). Phagocytosis on macrophages and neutrophils is significantly (* p<0.05) decreased in the CF (solid bar) vs. non-CF (open bar) subject groups. C and D show representative histograms of a non-CF and CF subject, respectively. Macrophage phagocytosis after zymosan exposure is shown as the dark histogram. No zymosan exposure is shown as the grey histogram. The M2 region indicates zymosan uptake by macrophages and M1 (control region) indicates no zymosan uptake. Journal of Cystic Fibrosis 2006 5, 17-25DOI: (10.1016/j.jcf.2005.11.001) Copyright © 2005 European Cystic Fibrosis Society Terms and Conditions

Fig. 3 BALF cell culture experiments measuring phagocytosis (A) and mCD14 expression (B) on macrophages obtained from 12 CF subjects 24h after incubation with SP-A, SP-D, or LPS. Phagocytosis (MFI, % change from control) was significantly increased following SP-A and SP-D incubation (*p<0.05). mCD14 expression (MFI, % change from control) was significantly increased following incubation with SP-A (*p<0.05). Journal of Cystic Fibrosis 2006 5, 17-25DOI: (10.1016/j.jcf.2005.11.001) Copyright © 2005 European Cystic Fibrosis Society Terms and Conditions

Fig. 4 BALF cell culture experiments measuring phagocytosis (A), mCD14 (B) and HLA-DR (C) expression on non-CF BALF cells after in vitro incubations with cell-free CF BALF, neutrophil elastase (NE) and these conditions with addition of proteinase inhibitor (PI). A: Phagocytosis was measured in macrophages (solid bar), monocytes (open bar) and neutrophils (horizontal hatch). Phagocytosis (MFI, % change from control) was significantly (*p<0.05) reduced for macrophages, monocytes and neutrophils following incubation with CF BALF (N=5); other conditions NS and not shown. B and C show surface marker expression after BALF+PI (N=5), NE (N=4) and NE+PI (N=4). Both, mCD14 (B) and HLA-DR (C) expression (MFI, as % change from control) were significantly decreased following incubation with CF BALF and NE (*p<0.05). PI significantly (# p<0.05) attenuated the NE-induced decrement in mCD14 and HLA-DR expression, but not the CF BALF-induced decrement. Journal of Cystic Fibrosis 2006 5, 17-25DOI: (10.1016/j.jcf.2005.11.001) Copyright © 2005 European Cystic Fibrosis Society Terms and Conditions